Targeting metabolic weaknesses in advanced prostate cancer treatment.
Targeting Metabolic Vulnerabilities with Synergistic Therapeutic Agents for Treatment of Metastatic Castration-Resistant Prostate Cancer.
This study is looking at new ways to treat advanced prostate cancer that doesn't respond to usual treatments by targeting how cancer cells use certain nutrients to survive, and it may involve patients trying out these new treatment combinations.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-10929951 on NIH RePORTER |
What this research studies
This research focuses on developing new therapeutic strategies for metastatic castration-resistant prostate cancer (mCRPC), a stage of prostate cancer that is particularly difficult to treat. The approach involves targeting specific metabolic pathways that cancer cells exploit to survive and resist standard treatments. By inhibiting key enzymes involved in glutamine metabolism, the research aims to enhance the effectiveness of existing therapies and potentially overcome drug resistance. Patients may be involved in trials assessing these new treatment combinations.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who have not responded to standard therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not progressed to the metastatic stage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced prostate cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
Austin, United States
- University of Texas at Austin — Austin, United States (Active)
Researchers
- Principal investigator: Hackman, Gabrelle Lavender — University of Texas at Austin
- Study coordinator: Hackman, Gabrelle Lavender
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.